Vericel (VCEL) Revenue Growth (1y) (2012 - 2026)
Vericel (VCEL) Revenue Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | - |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 473.74 Bn | 468.95 Bn | 1.35 Bn | 35.46% |
| 5 | Vertex Pharmaceuticals | 122.07 Bn | 114.82 Bn | 2.59 Bn | 7.82% |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.24 Bn | 3.31 Bn | 19.04% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | 64.03% |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 96.43% |
| 10 | Vericel | 2.33 Bn | 2.18 Bn | 49.27 Mn | 30.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.09% |
| Dec 31, 2025 | 23.27% |
| Sep 30, 2025 | 16.58% |
| Jun 30, 2025 | 20.09% |
| Mar 31, 2025 | 2.57% |
| Dec 31, 2024 | 15.97% |
| Sep 30, 2024 | 27.04% |
| Jun 30, 2024 | 14.68% |
| Mar 31, 2024 | 25.02% |
| Dec 31, 2023 | 23.35% |
| Sep 30, 2023 | 18.93% |
| Jun 30, 2023 | 24.70% |
| Mar 31, 2023 | 14.41% |
| Dec 31, 2022 | 10.72% |
| Sep 30, 2022 | 13.67% |
| Jun 30, 2022 | -6.81% |
| Mar 31, 2022 | 6.62% |
| Dec 31, 2021 | 5.22% |
| Sep 30, 2021 | 8.70% |
| Jun 30, 2021 | 97.46% |